Synergy Pharmaceuticals Inc. (NASDAQ: SGYP)

BiotechnologyNew York, United States51-200 Employees

Synergy Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for gastrointestinal diseases. Its work centers on uroguanylin analogs, a class of GI peptides under investigation to improve efficacy, safety, and tolerability for patients living with conditions such as chronic idiopathic constipation, irritable bowel syndrome with constipation, opioid-induced constipation, and ulcerative colitis. The company aims to deliver novel treatment options for patients and healthcare providers, supported by a long-running emphasis on science and innovation. Based in New York City, with research, technical operations, and commercial offices in the Philadelphia area, Synergy has historically positioned itself as a specialty GI-focused research organization with a history spanning more than two decades. The firm operates within the biotechnology research sector and maintains a relatively small to mid-size footprint, reflecting its focus on specialized drug development activities. Recent corporate developments indicate asset-related transactions involving the company and other industry players, highlighting shifts in its strategic portfolio within the broader GI therapeutics landscape.

Sign up for free to view info

Email Format Employee directory